Cash $18
In an internet discussion with a friend, he thought that early in the year, I was just shooting
from the hip, then life fell apart, and I was holding the bag on my little guys. Thought he
described me/things pretty well. He thought if I had to send him a blurb on why I bought every
time I bought a new little trader, or added to one, it might put me on a more even keel. After
mulling it over, I thought he might be on to something, but instead of sending him a blurb,
thought I would put it here. Maybe if will do me some good. Not planning on explaining what a
company does, as that can be found quick enough for anyone interested.
Now 590 +$4
10/13/2023 11:28:41 Bought 100 TBLA @ 3.7079 -370.79
10/13/2023 14:00:18 Bought 40 TBLA @ 3.64 -145.60
Last call on TIKR: Free accounts can see the last 45 days of calls.
app.tikr.com
"We're also excited to raise the midpoint of our full-year 2023 guidance. As we're getting closer to 2024,
we're bullish on our future. We expect a step change in our financial performance, and we're reiterating our
guidance for 2024 of over $200 million in adjusted EBITDA and over $100 million in free cash flow."
Past annual earnings -.36 / -.26 / -.05 / Estimates 2023 0n: +.02 / +.32 / +.40
Now 1025 -$653
10/13/2023 12:14:34 Bought 50 ADMA @ 3.1898 -159.49
Past annual earnings: -.88 / -.51 / -.33 / estimated 2023 on: -.7 / +.11 / +.32
Zacks:
"Market participants will be closely following the financial results of Adma Biologics in its upcoming release.
The company is forecasted to report an EPS of -$0.01, showcasing an 87.5% upward movement from the
corresponding quarter of the prior year. At the same time, our most recent consensus estimate is projecting
a revenue of $62.55 million, reflecting a 52.23% rise from the equivalent quarter last year.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of -$0.06 per share and a
revenue of $244.07 million, indicating changes of +81.82% and +58.41%, respectively, from the former year."
Last call on TIKR.
app.tikr.com
"The encouraging business trends and compelling forward-looking indicators have enabled ADMA to
increase fiscal year 2024 and fiscal year 2025 total revenue guidance to at least $275 million and $325
million, respectively, and otherwise reiterate confidence in meeting or exceeding all profitability targets." |
